Skip to main content

Veradermics, Inc (MANE)

Red

Health Care · As of 17 July 2026

Price chart — 52 weeks

MANE · 111.32 (last weekly close) SMA 10w SMA 40w
20406080100120MarAprMayJunJul5.0MWeek of Feb 2, 2026 · O 33.00 · H 40.11 · L 32.00 · C 38.48 · Vol 4.4MWeek of Feb 9, 2026 · O 37.91 · H 45.78 · L 36.26 · C 43.46 · Vol 1.6MWeek of Feb 16, 2026 · O 43.89 · H 51.56 · L 42.66 · C 44.49 · Vol 1.1MWeek of Feb 23, 2026 · O 44.28 · H 45.90 · L 39.73 · C 45.85 · Vol 1.3MWeek of Mar 2, 2026 · O 46.99 · H 51.03 · L 43.76 · C 48.56 · Vol 1.0MWeek of Mar 9, 2026 · O 48.93 · H 57.08 · L 48.93 · C 52.80 · Vol 1.6MWeek of Mar 16, 2026 · O 52.62 · H 63.03 · L 52.62 · C 58.89 · Vol 3.4MWeek of Mar 23, 2026 · O 59.01 · H 69.41 · L 58.96 · C 65.53 · Vol 2.0MWeek of Mar 30, 2026 · O 64.85 · H 66.60 · L 54.77 · C 64.19 · Vol 2.9MWeek of Apr 6, 2026 · O 64.43 · H 69.57 · L 53.68 · C 68.80 · Vol 1.8MWeek of Apr 13, 2026 · O 69.55 · H 80.90 · L 68.30 · C 76.29 · Vol 2.5MWeek of Apr 20, 2026 · O 75.91 · H 77.15 · L 65.80 · C 67.84 · Vol 1.4MWeek of Apr 27, 2026 · O 81.07 · H 114.50 · L 73.40 · C 101.00 · Vol 8.0MWeek of May 4, 2026 · O 100.95 · H 117.71 · L 99.50 · C 106.14 · Vol 3.8MWeek of May 11, 2026 · O 105.00 · H 112.51 · L 97.80 · C 99.72 · Vol 2.1MWeek of May 18, 2026 · O 99.27 · H 107.63 · L 95.70 · C 101.62 · Vol 1.7MWeek of May 25, 2026 · O 102.24 · H 107.95 · L 94.52 · C 100.91 · Vol 2.7MWeek of Jun 1, 2026 · O 101.40 · H 105.00 · L 90.36 · C 91.69 · Vol 2.5MWeek of Jun 8, 2026 · O 93.79 · H 100.40 · L 90.18 · C 96.07 · Vol 1.8MWeek of Jun 15, 2026 · O 96.74 · H 97.83 · L 86.83 · C 93.87 · Vol 2.1MWeek of Jun 22, 2026 · O 96.03 · H 128.24 · L 95.93 · C 126.89 · Vol 7.6MWeek of Jun 29, 2026 · O 126.71 · H 131.24 · L 120.00 · C 129.74 · Vol 2.7MWeek of Jul 6, 2026 · O 128.11 · H 129.81 · L 116.19 · C 119.60 · Vol 2.0MWeek of Jul 13, 2026 · O 119.73 · H 129.80 · L 104.46 · C 111.32 · Vol 4.7M111
Weekly candles over the last 52 weeks, split-adjusted, with 10- and 40-week moving averages; trading volume along the bottom. As of Jul 13, 2026.

OakBag could not build a reliable fair-value estimate for Veradermics, Inc (MANE) — none of its valuation methods cleared the model's safety checks (typically a company running an operating loss, where a discount can't be trusted). At a recent price of $111.32 the traffic light is set so it looks expensive or risky, benchmarked against other Health Care names. This is a model output for research, not a price target or a recommendation.

Fair value vs. price

Current price
$111.32
Estimated fair value
Margin of safety

How the fair value is built

How is this computed?

Why not green?

  • The company is running an operating loss, so the screen will not flag a money-losing business as a buy.
  • Only one valuation method applies to this business — too thin to flag as a buy on its own.

Knock-out safety checks passed

  • Bankruptcy risk (Altman Z″)
  • Negative equity
  • Excessive leverage
  • Illiquid
  • Penny / micro-cap
  • Stale fundamentals
Piotroski F-score
2 / 9
Altman Z-score
68.31
Beneish M-score
-2.20

Quality & factor profile

Value -0.41
Quality -0.53
Profitability -0.50
Momentum +0.00
Growth +0.00
Low volatility -2.25

See the full analysis

Create a free OakBag account to unlock every valuation method, price history, watchlists and email alerts for MANE and 1,850+ other stocks.

No credit card · just an email

Frequently asked questions

Is Veradermics (MANE) undervalued?

OakBag could not build a reliable fair-value estimate for Veradermics, Inc — none of its valuation methods cleared the model's safety checks, which usually happens for a company running an operating loss. At a recent price of $111.32 the model looks expensive or risky. This is a model output, not investment advice.

What is margin of safety?

Margin of safety is how far below the estimated fair value the price sits: (fair value − price) ÷ fair value. It cannot be shown here because no reliable fair-value estimate could be built for this stock.

Does a green verdict mean I should buy MANE?

No. OakBag is an educational and research tool, not investment advice. The traffic light is an automated model output based on third-party data that may be delayed or inaccurate. Always do your own research.

Other Health Care stocks

An educational and research tool — not investment advice. OakBag is an educational and research tool, not investment advice. Scores and rankings are automated model outputs based on third-party data and may be inaccurate or delayed. Nothing here is a recommendation to buy or sell any security. Investing involves risk, including possible loss of principal.